Orexo bags milestone for novel painkiller candidate from Boehringer Ingelheim
Uppsala/Ingelheim – Swedish pain and inflammation specialist Orexo AB has received a US$6.5m milestone from Boehringer Ingelheim for a painkiller targeting inhibition of prostaglandin (PGE2) synthesis. PEG2 is central to diverse inflammatory processes and PEG2 inhibition is thought to provide a novel mechanism to block inflammatory pain with less adverse effects than existing painkillers and inflammation blockers, such as NSAIDs. According to the cooperation agreement, which was signed in 2005 by Boehringer and Biolipox (acquired in 2007 by Orexo), the Swedish firm will have the option for further milestones and royalties. Boehringer Ingelheim will be responsible for all further compound development and marketing. In the Nordic and Baltic countries, Orexo has the option to co-promote the products arising from this collaboration. The co-promotion option would enable Orexo to build up its own commercialisation capabilities within the field of inflammatory pain.